Quantcast

Industry news that matters to you.  Learn more

Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics

Reading time: 2 – 3 minutes

Genomic Health, Inc. (Nasdaq: GHDX) recently announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment.
“By providing quantitative information which has not been available with conventional measures, as demonstrated in this analysis, the Oncotype DX colon cancer test is likely to lead to both savings in direct medical costs and improved patient well-being,” said Steven Alberts, M.D., chair, division of Medical Oncology at the Mayo Clinic, Rochester, Minn.

The analysis of 141 patients from 17 sites in the Mayo Clinic Cancer Research Consortium demonstrated the value of using the Oncotype DX test to identify stage II colon cancer patients with low risk of recurrence, who may consider forgoing a chemotherapy regimen. After physicians received the Recurrence Score results, their recommendations for adjuvant chemotherapy in patients with low risk of recurrence decreased by 22 percent, which resulted in direct medical care cost savings of approximately $1,000 per patient. This is the first health economic study of the Oncotype DX colon cancer test conducted in clinical practice. A previous, separate modeling study showing that the use of the Oncotype DX test in stage II colon cancer patients may lead to health care cost savings while improving clinical outcomes was published in 2012 by Value of Health.

“This publication highlights the important role of the Oncotype DX colon cancer test in delivering personalized medicine to the modern paradigm for cancer care,” said George Kim, M.D., gastrointestinal oncologist, 21st Century Oncology, Jacksonville, Fla. “By enabling a more individualized approach to my patients’ treatment, the test not only saves health care dollars but also improves their well-being and can prevent individual non-direct costs associated with potentially unnecessary treatment, related time away from work and increased household care needs. This trial is an important landmark highlighting the advantages of individualized care in terms of treatment benefit, toxicity and cost.”

Source: Genomic Health